Bupivacaine 2% Infiltration in Tubeless Percutaneous Nephrolithotomy in singular stone of the pelvis

The Efficacy of Bupivacaine 2% Infiltration in Tubeless Percutaneous Nephrolithotomy in singular stone of the pelvis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221108056446N17

Enrollment

Registered

2025-06-12

Start date

2025-07-06

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Singular pelvic stone. Retained stone or crystalline fragments

Interventions

Intervention 1: Intervention group: Patients in the intervention group will receive 20 ml infiltration and 0.25% bupivacaine, and then the amplicons will be removed. Intervention 2: Control group: In

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients under 18 years of age Patients with solitary pelvic stones less than 3 cm who require PCNL

Exclusion criteria

Exclusion criteria: Need for more than one percutaneous route during surgery Damage to the pleura and other organs during surgery Need for nephrostomy placement Associated hydronephrosis Kidney failure Ureteral-pelvic junction obstruction Simultaneous bilateral PCNL Body mass index greater than 40 History of cancer Double J embedding history Addiction

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: The day after surgery. Method of measurement: Visual Analogue Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Kazemi

Esfahan University of Medical Sciences

Rezakazemi6788@gmail.com+98 913 086 1885

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026